Multi-institutional development and external validation of machine learning-based models to predict relapse risk of pancreatic ductal adenocarcinoma after radical resection

Abstract

Background Surgical resection is the only potentially curative treatment for pancreatic ductal adenocarcinoma (PDAC) and the survival of patients after radical resection is closely related to relapse. We aimed to develop models to predict the risk of relapse using machine learning methods based on multiple clinical parameters. Methods Data were collected and analysed of 262 PDAC patients who underwent radical resection at 3 institutions between 2013 and 2017, with 183 from one institution as a training set, 79 from the other 2 institution as a validation set. We developed and compared several predictive models to predict 1- and 2-year relapse risk using machine learning approaches. Results Machine learning techniques were superior to conventional regression-based analyses in predicting risk of relapse of PDAC after radical resection. Among them, the random forest (RF) outperformed other methods in the training set. The highest accuracy and area under the receiver operating characteristic curve (AUROC) for predicting 1-year relapse risk with RF were 78.4% and 0.834, respectively, and for 2-year relapse risk were 95.1% and 0.998. However, the support vector machine (SVM) model showed better performance than the others for predicting 1-year relapse risk in the validation set. And the k neighbor algorithm (KNN) model achieved the highest accuracy and AUROC for predicting 2-year relapse risk. Conclusions By machine learning, this study has developed and validated comprehensive models integrating clinicopathological characteristics to predict the relapse risk of PDAC after radical resection which will guide the development of personalized surveillance programs after surgery.

A Novel Small Molecular Prostaglandin Receptor EP4 Antagonist, L001, Suppresses Pancreatic Cancer Metastasis

“…The liver is the most common metastatic organ of pancreatic cancer [36]. Liver metastasis of pancreatic cancer exhibits three main fatal characteristics, including small tumors with advanced metastases, rapid relapse after radical resection and extremely short survival rate, of within only 3-6 months [37,38]. The current first-line chemotherapies, including gemcitabine or FOLFIRINOX, have limited benefits for metastatic pancreatic cancer, with a median overall survival of less than a year [7].…”

Identification of a Novel Risk Model: A Five-Gene Prognostic Signature for Pancreatic Cancer

“…At present, radical surgical resection is regarded as the standard and most effective remedy. However, the recurrence rate of PCa is pretty high [30,31]. Molecular biomarkers are a typically strategy for prognosis evaluation of diseases.…”

Artificial intelligence in pancreatic cancer

“…These facts make it challenging to predict the prognosis of PC. Due to its excellent computational power, AI was used to analyze PC prognoses, including survival time [204][205][206][207][208][209][210][211][212][213][214][215][216][217][218][219][220][221], recurrence risk [78,[221][222][223][224], metastasis [225][226][227][228][229][230], therapy response [79][80][81][231][232][233][234][235][236][237][238][239][240], etc.…”